Cite
HARVARD Citation
Weetall, M. et al. (n.d.). Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation. Clinical pharmacology in drug development. 5 (4), pp. 296-305. [Online].